Potential role of linagliptin as an oral once-daily treatment for patients with type 2 diabetes
Lene Hoimark, Torben Laursen, Jørgen RungbyDepartment of Biomedicine – Pharmacology and Clinical Pharmacology, Aarhus University Hospital and Aarhus University, Aarhus, DenmarkBackground: Linagliptin is an oral antihyperglycemic agent that selectively inhibits the enzyme...
Guardado en:
Autores principales: | Hoimark L, Laursen T, Rungby J |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9e9a08294b40482b99b4feb3ff8beb1c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
por: Petersen AB, et al.
Publicado: (2013) -
Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
por: Scott D
Publicado: (2013) -
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz B
Publicado: (2013) -
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
por: Mann KV, et al.
Publicado: (2014) -
Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders WB, et al.
Publicado: (2016)